Hidden Blood-Brain Barrier in Lung Cancer Blocks Immunotherapy From Working
Researchers discover a BBB-like vascular shield in small cell lung cancer that blocks immune cells — and find a drug combo to overcome it.
Summary
Small cell lung cancer (SCLC) is notoriously resistant to immunotherapy, but scientists have now uncovered a surprising reason why. Tumors in SCLC build a structural barrier around their blood vessels that closely resembles the blood-brain barrier — tightly sealed endothelial cells, a thickened membrane, and dense pericyte coverage — that physically blocks immune cells from entering the tumor. This barrier is driven by a master transcription factor called ASCL1, which triggers a signaling cascade through IGFBP5 and IGF1R. Blocking this pathway with an existing drug (OSI-906, an IGF1R inhibitor) dismantled the barrier, allowed CD8+ T cells to infiltrate, and dramatically improved the effectiveness of anti-PD1 immunotherapy in preclinical models. The same barrier appears in other neuroendocrine cancers, opening a broad new therapeutic avenue.
Detailed Summary
Small cell lung cancer (SCLC) is one of the most aggressive and treatment-resistant cancers known. Despite the success of immunotherapy in many solid tumors, SCLC responds poorly to checkpoint inhibitors like anti-PD1 drugs. Until now, the precise mechanisms behind this resistance have remained elusive.
Researchers at West China Hospital, Sichuan University, and collaborating institutions discovered that SCLC tumors construct a blood-brain barrier-like vascular gate (BVG) — a structural shield around tumor blood vessels not seen in non-small cell lung cancer or most other cancers. This barrier consists of tightly connected endothelial cells, a thickened basement membrane, and dense pericyte coverage, effectively preventing cytotoxic immune cells from infiltrating the tumor microenvironment.
The team traced the formation of this barrier to ASCL1, the master transcription factor that defines SCLC's neuroendocrine identity. ASCL1 upregulates IGFBP5, which in turn activates IGF1 signaling in endothelial cells, instructing them to form the BBB-like structure. When researchers knocked out IGFBP5 or treated tumors with OSI-906 — an IGF1R inhibitor already in clinical development — the barrier broke down, CD8+ T cell infiltration increased markedly, and anti-PD1 therapy became significantly more effective.
Critically, this ASCL1-IGFBP5-IGF1R axis and the BVG are conserved across multiple neuroendocrine cancers, suggesting the finding extends well beyond SCLC to tumors of the pancreas, gut, and other neuroendocrine tissues.
The implications are substantial: this research reframes immunotherapy failure in SCLC as a vascular exclusion problem rather than purely a tumor-intrinsic or immune-cell deficiency. Combining IGF1R inhibition with checkpoint blockade could represent a clinically actionable strategy. Caveats include the study's preclinical nature and limited translational data in humans.
Key Findings
- SCLC tumors form a BBB-like vascular gate that physically blocks immune cell infiltration into the tumor.
- The ASCL1 transcription factor drives barrier formation via IGFBP5-IGF1R signaling in endothelial cells.
- Blocking IGF1R with OSI-906 dismantles the barrier and boosts CD8+ T cell tumor infiltration.
- Combining OSI-906 with anti-PD1 therapy showed synergistic anti-tumor effects in preclinical models.
- The same BBB-like vascular barrier is conserved across multiple neuroendocrine cancer types.
Methodology
The study combined tumor microenvironment analysis of SCLC patient samples, comparison with NSCLC and other cancers, mechanistic dissection of the ASCL1-IGFBP5-IGF1R axis, and preclinical intervention experiments using IGFBP5 knockout and the IGF1R inhibitor OSI-906 in combination with anti-PD1 therapy. Findings were validated across multiple neuroendocrine cancer types.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting detailed methodological evaluation. The key intervention experiments appear to be preclinical, so human clinical validation remains to be established. The generalizability to all neuroendocrine cancers requires further confirmation in dedicated clinical studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.